Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sigyn Therapeutics Inc (QB) | SIGY | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.25 | 5.25 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 0.052 - 6.34 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 5.25 | USD |
Sigyn Therapeutics Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 232.18M | 44.22M | 8.63M | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sigyn Therapeutics (QB) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SIGY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 6.25 | 6.34 | 5.00 | 5.42 | 337 | -1.00 | -16.00% |
3 Months | 5.00 | 6.34 | 4.50 | 5.33 | 342 | 0.25 | 5.00% |
6 Months | 0.176 | 6.34 | 0.09 | 0.2959414 | 5,536 | 5.07 | 2,882.95% |
1 Year | 0.11 | 6.34 | 0.052 | 0.1955401 | 8,763 | 5.14 | 4,672.73% |
3 Years | 1.35 | 6.34 | 0.052 | 0.3218469 | 7,988 | 3.90 | 288.89% |
5 Years | 1.8501 | 6.34 | 0.052 | 0.5338303 | 6,228 | 3.40 | 183.77% |
Sigyn Therapeutics (QB) Description
Sigyn Therapeutics is a development-stage company focused on creating therapeutic solutions to address unmet needs in global health. Sigyn Therapy, the Companys lead product candidate, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders that are not addressed with approved drug therapies. Candidate treatment indications for Sigyn Therapy include chronic inflammation and endotoxemia in end-stage renal disease patients, sepsis (leading cause of hospital deaths), community acquired pneumonia (a leading cause of death among infectious diseases), and emerging pandemic threats. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the delivery of FDA approved chemotherapeutic agents and ChemoPure to reduce chemotherapy toxicity. |